TY - JOUR AU - Tay, Rebecca Yin AU - Ackermann, Christoph Jakob AU - Califano, Raffaele PY - 2018 TI - Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer JF - Translational Lung Cancer Research; Vol 7, Supplement 4 (December 30, 2018): Translational Lung Cancer Research Y2 - 2018 KW - N2 - In patients with advanced non-small cell lung cancer (NSCLC) whose tumour harbour a sensitising epidermal growth factor receptor (EGFR) mutation, international guidelines recommend first-line therapy with an EGFR tyrosine kinase inhibitor (TKI) due to longer progression free survival (PFS), higher overall response rate (ORR) and improved quality of life compared to platinum doublet chemotherapy (1,2). UR - https://tlcr.amegroups.org/article/view/24510